North America Autoimmunity Diagnostics Market (2025-2030)
The North America Autoimmunity Diagnostics Market was valued at $1257.6 Million in 2025 and projected to reach to $1966.3 Million by 2030, representing a compound annual growth rate of 7.7%. North America's autoimmunity diagnostics market is poised for sustained expansion through 2030, supported by increasing autoimmune disease incidence, aging populations, and heightened clinical awareness.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America Autoimmunity Diagnostics Market Trends and Insights
- This 7.7% compound annual growth rate reflects North America's advanced healthcare infrastructure, high prevalence of autoimmune disorders, and strong adoption of diagnostic technologies.
- North America leads globally in precision medicine and early disease detection, driving demand for sophisticated autoimmunity testing platforms. The North America market benefits from established reimbursement frameworks, significant R&D investments, and a concentration of leading diagnostic manufacturers.
- North America's aging population and rising autoimmune disease incidence are key catalysts for market expansion through 2030.
- Healthcare providers across North America are increasingly integrating multiplex and point-of-care autoimmunity diagnostics into clinical workflows, supporting sustained market growth..
Key Market Statistics
- CAGR (2025-2030) 7.7% CAGR
- Market Size, 2025 ~USD 1257.6 Million
- Forecast, 2030 ~USD 1966.3 Million
- Geography North America
North America Autoimmunity Diagnostics Market Overview
Market Leadership Position :
North America commands the largest share of the global autoimmunity diagnostics market, driven by advanced healthcare infrastructure, high diagnostic adoption rates, and significant investment in precision medicine technologies across the US and Canada.
Strong CAGR Growth :
The region is projected to grow at 7.7% CAGR from 2025 to 2030, expanding from $1,257.6 million to $1,966.3 million, reflecting increasing autoimmune disease prevalence and rising demand for early detection solutions.
High Disease Prevalence :
North America has one of the highest prevalence rates of autoimmune disorders globally, with millions of patients requiring continuous diagnostic monitoring, creating sustained demand for innovative testing solutions and biomarker discovery.
Precision Medicine Innovation Hub :
The region leads in developing and adopting cutting-edge diagnostic technologies including multiplex assays, AI-driven analytics, and personalized testing platforms, supported by robust R&D ecosystems and regulatory frameworks.
North America Autoimmunity Diagnostics Market Dynamics
- The region's advanced healthcare systems and strong reimbursement policies create favorable conditions for diagnostic innovation and market penetration.
- Key growth drivers include the shift toward early diagnosis, integration of digital health platforms, and development of multiplex testing solutions that improve patient outcomes and reduce healthcare costs. The competitive landscape in North America remains dynamic, with established diagnostic companies and emerging biotech firms investing heavily in next-generation testing platforms.
- Regulatory support from the FDA and Health Canada, combined with strong healthcare spending, positions North America as the primary market for autoimmunity diagnostic innovations.
- Strategic partnerships between diagnostic providers and healthcare systems are expected to accelerate adoption rates and expand market opportunities through 2030..
Related Ecosystem
Analytical And Scientific Instrumentation
- Environmental Testing
- Gas Chromatography
- Polymerase Chain Reaction (PCR)
- Automated Liquid Handling Systems
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Agilent Technologies, Inc.
- Merck KGaA
- Shimadzu Corporation
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Key Takeaways
- North America's autoimmunity diagnostics market will grow from $1,257.6M (2025) to $1,966.3M (2030) at a 7.7% CAGR.
- North America's advanced healthcare infrastructure and high autoimmune disease prevalence drive strong diagnostic adoption.
- Established reimbursement policies and significant R&D investments position North America as a market leader.
- North America's aging population and rising disease incidence will sustain market expansion through 2030.
Autoimmunity Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | AUTOANTIBODIES AND IMMUNOLOGIC TESTS (Test Type) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 8.3% from 2025 to 2030 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 5.57 (2025) |
| Revenue Forecast (Billions) | ~USD 8.29 (2030) |
| Segments Covered | Product, Test Type, Disease Type, Type, End User |
North America Autoimmunity Diagnostics Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product
- Consumables
- Instruments
By Test Type
- Autoantibodies And Immunologic Tests
- Inflammatory Tests
- Other Tests
- Routine Laboratory Tests
- Urinalysis Tests
By Disease Type
- Organ-Specific Autoimmune Diseases
- Systemic Autoimmune Diseases
By Type
- Celiac Disease
- Inflammatory Bowel Disease
- Multiple Sclerosis
- Other Organ-Specific Autoimmune Diseases
- Other Systemic Autoimmune Diseases
- Psoriasis
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Type-1 Diabetes
By End User
- Clinical Laboratories
- Hospitals & Clinics
- Other End Users
Target Audience
- Diagnostic Device Manufacturers : Need regional market sizing and growth forecasts to guide R&D investment, product launches, and market entry strategies in the high-value North American autoimmunity diagnostics segment.
- Healthcare System Administrators : Require market intelligence on diagnostic adoption trends, cost-effectiveness data, and competitive offerings to optimize procurement decisions and improve patient diagnostic pathways across North American healthcare networks.
- Investment & Private Equity Firms : Seek validated market data and growth projections for North America to evaluate investment opportunities in diagnostic companies, assess portfolio company performance, and identify acquisition targets in the autoimmunity space.
- Pharmaceutical & Biotech Companies : Need market context on diagnostic companion tools and biomarker testing trends in North America to support drug development strategies, clinical trial design, and companion diagnostic commercialization plans.
- Healthcare Consultants & Analysts : Require comprehensive regional market data and forecasts to support client advisory work, competitive benchmarking, and strategic planning for healthcare organizations and diagnostic industry stakeholders.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 1759.4 Million |
| Canada | USD 293.5 Million |
Country market size visualization
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation for North America ($1,257.6M in 2025) with verified CAGR of 7.7% through 2030, enabling accurate financial forecasting and investment decision-making for regional expansion strategies.
- Country-Level Intelligence : Access detailed market breakdowns for US ($1,759.4M) and Canada ($293.5M), allowing stakeholders to identify high-opportunity markets and tailor go-to-market strategies by country-specific dynamics and healthcare regulations.
- Competitive Positioning Insights : Understand North America's leadership position relative to global markets (8.3% global CAGR vs. 7.7% regional), revealing competitive advantages, market saturation levels, and opportunities for differentiation in precision diagnostics.
- Regulatory & Reimbursement Context : Gain insights into North America's advanced healthcare infrastructure, FDA approval pathways, and reimbursement landscapes that drive diagnostic adoption, essential for product development and commercialization planning.
- Strategic Growth Opportunities : Identify emerging trends in multiplex testing, AI-driven diagnostics, and personalized medicine adoption specific to North America, enabling companies to align product pipelines with regional market demands and capture growth segments.
Frequently asked questions
What is the current size of North America's autoimmunity diagnostics market?
North America's autoimmunity diagnostics market is valued at $1,257.6 million in 2025.
What is the projected market size for North America by 2030?
North America's autoimmunity diagnostics market is forecast to reach $1,966.3 million by 2030.
What is the CAGR for North America's autoimmunity diagnostics market?
North America's autoimmunity diagnostics market is expected to grow at a 7.7% compound annual growth rate from 2025 to 2030.
What factors are driving growth in North America's autoimmunity diagnostics market?
North America's market growth is driven by advanced healthcare infrastructure, high autoimmune disease prevalence, established reimbursement frameworks, significant R&D investments, and an aging population.
How does North America's autoimmunity diagnostics market compare to global trends?
North America's 7.7% CAGR slightly lags the global 8.3% CAGR, but North America maintains leadership through superior healthcare infrastructure and diagnostic technology adoption.
RESEARCH METHODOLOGY
The study involved estimating activities to determine the current size of the autoimmunity diagnostics market. Exhaustive secondary research was done to collect information on the autoimmunity diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the autoimmunity diagnostics market.
Secondary Research
Various sources were utilized to gather information for this study in the secondary research process. These sources included company annual reports, press releases, and investor presentations; white papers; certified publications; articles by recognized authors; reputable websites; and information from regulatory bodies and databases, such as D&B Hoovers, Bloomberg Business, and Factiva.
Primary Research
In the primary research process, various sources from both the supply & demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| Abbott Laboratories (US) | Product Specialist |
| Thermo Fisher Scientific Inc. (US) | Clinical Sales Specialist |
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the autoimmunity diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry were identified through extensive secondary research.
- Primary and secondary research determined the revenues generated by leading players operating in the autoimmunity diagnostics market.
- All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments after arriving at the overall market size by applying the abovementioned process. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Autoimmune diseases are defined as a medical condition in which an individual's immune system produces antibodies that attack the body's normal tissues. autoimmunity diagnostics systematically identifies autoimmune disorders through clinical assessment and laboratory investigations to detect immune system dysfunction. This process typically involves routine laboratory testing, measurement of systemic inflammatory markers, detection of disease-specific autoantibodies, urinalysis, and other specialized immunologic assays.
Stakeholders
- Manufacturers & distributors of autoimmunity diagnostics products
- Clinical laboratories
- Hospitals
- Research institutes
- Government associations
- Venture capitalists & investors
Report Objectives
- To define, describe, segment, and forecast the global autoimmunity diagnostics market, by product, test type, disease type, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall autoimmunity diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Get the Full Autoimmunity Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Autoimmunity Diagnostics Market.
- US Autoimmunity Diagnostics Market
- Canada Autoimmunity Diagnostics Market
- UK Autoimmunity Diagnostics Market
- Germany Autoimmunity Diagnostics Market
- France Autoimmunity Diagnostics Market
- Italy Autoimmunity Diagnostics Market
- Spain Autoimmunity Diagnostics Market
- China Autoimmunity Diagnostics Market
- Japan Autoimmunity Diagnostics Market
- India Autoimmunity Diagnostics Market
- Australia Autoimmunity Diagnostics Market
- Rest Of Europe Autoimmunity Diagnostics Market
- Rest Of Asia Pacific Autoimmunity Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
